Actualités de la communauté

26.08.2019 ADC Therapeutics and Freenome Enter Biomarker Development Collaboration

ADC Therapeutics to employ Freenome’s multiomics platform to identify biomarkers that correlate with clinical response to ADCT-402 (loncastuximab tesirine)

LAUSANNE, Switzerland and SOUTH SAN FRANCISCO, Calif., August 26, 2019 – ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of antibody drug conjugates (ADCs), and Freenome, a biotechnology company that has pioneered the most comprehensive multiomics platform for early cancer detection through a routine blood draw, today announced that they have entered a biomarker development collaboration in which ADC Therapeutics will use Freenome’s platform to identify patients who are most likely to respond to treatment with ADCT-402 (loncastuximab tesirine). ADC Therapeutics is currently evaluating ADCT-402 in a pivotal Phase II clinical trial in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Freenome’s platform will characterize tumor heterogeneity and systemic immune response to identify signatures from blood of DLBCL patients participating in ADC Therapeutics’ pivotal Phase II clinical trial. The multiomics approach will allow ADC Therapeutics to consider a broad range of DNA, RNA and protein markers in developing a biomarker signature.

Full press release

retour